Targeting vasculogenesis to prevent progression in multiple myeloma

Leukemia

Volumn 30, Issue 5, 2016, Pages 1103-1115

  Moschetta, M ^a,b   Mishima, Y ^a   Kawano, Y ^a   Manier, S ^a   Paiva, B ^c   Palomera, L ^d   Aljawai, Y ^a   Calcinotto, A ^e   Unitt, C ^f   Sahin, I ^a   Sacco, A ^a   Glavey, S ^a   Shi, J ^g   Reagan, M R ^a,h   Prosper, F ^c   Bellone, M ^e   Chesi, M ⁱ   Bergsagel, L P ⁱ   Vacca, A ^b   Roccaro, A M ^a,j   Ghobrial, I M ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f DANA FARBER HARVARD CANCER CENTER   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h Maine Medical Center Research Institute   (United States)

ⁱ MAYO CLINIC   (United States)

^j SPEDALI CIVILI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY DC101; RNA; ANTIBODY; KDR PROTEIN, MOUSE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CLONE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EARLY CANCER; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; STEM CELL MOBILIZATION; STEM CELL NICHE; ANIMAL; BONE MARROW; CELL MOTION; DISEASE COURSE; IMMUNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SECONDARY PREVENTION; VASCULARIZATION;

ANIMALS; ANTIBODIES; BONE MARROW; CELL MOVEMENT; CLONE CELLS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; MICE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; SECONDARY PREVENTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84960349515     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.3     Document Type: Article

References (42)

1. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003; 45: 227-244.
2. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hemato-logic malignancies. Crit Rev Oncol Hematol 2007; 62: 105-118.
3. Eleutherakis-Papaiakovou V, Karali M, Kokkonouzis I, Tiliakos I, Dimopoulos MA. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. Leuk Lymphoma 2003; 44: 937-948.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angio-genesis. Nature 2011; 473: 298-307.
5. Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008; 143: 622-631.
6. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR et al. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol 2011; 154: 533-535.
7. Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M, Vacca A. Bone marrow angiogenesis and progression in multiple myeloma. Am J Bood Res 2011; 1: 76-89.
8. Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer 2011; 2: 1085-1096.
9. Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca et al. Role of endo-thelial progenitor cells in cancer progression. Biochim Biophys Acta 2014; 1846: 26-39.
10. Bhutani M, Turkbey B, Tan E, Kemp TJ, Pinto LA, Berg AR et al. Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia 2014; 28: 413-416.
11. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
12. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
13. Martin-Ramirez J, Hofman M, van den Biggelaar M, Hebbel RP, Voorberg J. Establishment of outgrowth endothelial cells from peripheral blood. Nat Protoc 2012; 7: 1709-1715.
14. Azab AK, Sahin I, Azab F, Moschetta M, Mishima Y, Burwick N et al. CXCR7-dependent angiogenic mononuclear cells trafficking regulates tumor progression in multiple myeloma. Blood 2014; 124: 1905-1914.
15. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123: 1542-1555.
16. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376-385.
17. Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 2014; 123: 4120-4131.
18. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011; 332: 687-696.
19. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol 2012; 30: 858-867.
20. Susaki EA, Tainaka K, Perrin D, Kishino F, Tawara T, Watanabe TM et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell 2014; 157: 726-739.
21. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link et al. Circulating endo-thelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
22. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
23. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F et al. Redefining endo-thelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-1809.
24. Yoder MC, Ingram DA. The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim Biophys Acta 2009; 1796: 50-54.
25. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-3294.
26. Bhaskar A, Gupta R, Kumar L, Sharma A, Sharma MC, Kalaivani M et al. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk Lymphoma 2012; 53: 635-640.
27. Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E et al. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov 2012; 2: 434-449.
28. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 2008; 118: 1380-1389.
29. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-180.
30. Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I et al. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Oncoimmunology 2015; 4: e1008850.
31. Mitsiades CS, Anderson KC, Carrasco DR. Mouse models of human myeloma. Hematol Oncol Clin North Am 2007; 21: 1051-1069, viii.
32. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
33. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116.
34. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xeno-grafts. Nature 1999; 401: 670-677.
35. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
36. Ciarrocchi A, Jankovic V, Shaked Y, Nolan DJ, Mittal V, Kerbel RS et al. Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One 2007; 2: e1338.
37. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009; 1796: 33-40.
38. Roodhart JM, Langenberg MH, Daenen LG, Voest EE. Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochim Biophys Acta 2009; 1796: 41-49.
39. De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011; 17: 1935-1946.
40. Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23: 5334-5346.
41. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184-191.
42. Moschetta M, Di Pietro G, Ria R, Gnoni A, Mangialardi G, Guarini et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010; 46: 420-429.